share_log

UBS Downgrades Cano Health to Neutral, Lowers Price Target to $1.25

Benzinga Real-time News ·  Jan 6, 2023 07:57

UBS analyst Andrew Mok downgrades Cano Health (NYSE:CANO) from Buy to Neutral and lowers the price target from $12 to $1.25.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment